Screening and Stability Evaluation of Freeze-Dried Protective Agents for a Live Recombinant Pseudorabies Virus Vaccine

Yan Liu,Suling Zhang,Shuai Wang,Chunhui Zhang,Xiaorui Su,Linghua Guo,Xiaofei Bai,Yuxin Huang,Wenqiang Pang,Feifei Tan,Kegong Tian

DOI: https://doi.org/10.3390/vaccines12010065

2024-01-10

Vaccines

Abstract:Infection of pigs with the pseudorabies virus (PRV) causes significant economic losses in the pig industry. Immunization with live vaccines is a crucial aspect in the prevention of pseudorabies in swine. The TK/gE/gI/11k/28k deleted pseudorabies vaccine is a promising alternative for the eradication of epidemic pseudorabies mutant strains. This study optimized the lyophilization of a heat-resistant PRV vaccine to enhance the quality of a live vaccine against the recombinant PRV rHN1201TK−/gE−/gI−/11k−/28k−. The A4 freeze-dried protective formulation against PRV was developed by comparing the reduction in virus titer after lyophilization and after seven days of storage at 37 °C. The formulation contains 1% gelatin, 5% trehalose, 0.5% poly-vinylpyrimidine (PVP), 0.5% thiourea, and 1% sorbitol. The A4 freeze-dried vaccine demonstrated superior protection and thermal stability. It experienced a freeze-dried loss of 0.31 Lg post-freeze-drying and a heat loss of 0.42 Lg after being stored at a temperature of 37 °C for 7 consecutive days. The A4 freeze-dried vaccine was characterized through XRD, FTIR, and SEM analyses, which showed that it possessed an amorphous structure with a consistent porous interior. The trehalose component of the vaccine formed stable hydrogen bonds with the virus. Long-term and accelerated stability studies were also conducted. The A4 vaccine maintained viral titer losses of less than 1.0 Lg when exposed to 25 °C for 90 days, 37 °C for 28 days, and 45 °C for 7 days. The A4 vaccine had a titer loss of 0.3 Lg after storage at 2–8 °C for 24 months, and a predicted shelf life of 6.61 years at 2–8 °C using the Arrhenius equation. The A4 freeze-dried vaccine elicited no side effects when used to immunize piglets and produced specific antibodies. This study provides theoretical references and technical support to improve the thermal stability of recombinant PRV rHN1201TK−/gE−/gI−/11k−/28k− vaccines.

immunology,medicine, research & experimental

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to improve the thermal stability and freeze - drying protection effect of the live Pseudorabies virus (PRV) vaccine. Specifically, the research aims to optimize the freeze - drying protectant formulation to enhance the stability of the recombinant Pseudorabies virus rHN1201TK−/gE−/gI−/11k−/28k− vaccine during the freeze - drying process and storage, thereby ensuring that the vaccine remains highly effective during transportation and storage.

### Main problems:
1. **Improve the thermal stability of the vaccine**: Traditional Pseudorabies virus vaccines are very sensitive to temperature, and long - term exposure at room temperature may lead to their inactivation or a decrease in infectivity. Therefore, it is necessary to develop a heat - resistant vaccine to meet the cold - chain challenges in transportation and storage.

2. **Optimize the freeze - drying protectant formulation**: Freeze - drying technology is a common method to improve the biological activity of live vaccines, but the freeze - drying process may cause virus damage. In order to reduce this damage, it is necessary to screen out the best combination of freeze - drying protectants to ensure that the vaccine maintains high activity during freeze - drying and storage.

### Research background:
- Pseudorabies (PR) is a highly contagious disease caused by the Pseudorabies virus (PRV), which causes significant economic losses to the pig - raising industry.
- At present, the most effective preventive measure is vaccination, especially the gene - deleted PRV vaccines (such as gE - deleted vaccines) have been widely used.
- Emerging PRV variants make disease control more complex, so it is necessary to develop more effective vaccines to deal with these new strains.
- Freeze - drying technology can improve the stability of vaccines, but it may cause virus inactivation or a decrease in infectivity during the freeze - drying process.

### Research objectives:
By screening and evaluating different freeze - drying protectant formulations, find an optimal formulation that can significantly improve the thermal stability and freeze - drying protection effect of the recombinant Pseudorabies virus rHN1201TK−/gE−/gI−/11k−/28k− vaccine. This will help improve the preservation performance of the vaccine in a high - temperature environment and reduce the dependence on cold - chain transportation.

### Conclusion:
Through experiments, the researchers found that formulation A4 (containing 1% gelatin, 5% trehalose, 0.5% polyvinylpyrrolidone, 0.5% thiourea and 1% sorbitol) showed the best freeze - drying protection effect and thermal stability. This formulation not only had less loss during the freeze - drying process, but also could maintain a relatively high virus titer under high - temperature storage conditions. In addition, the A4 vaccine produced specific antibodies after immunizing piglets, and no side effects were observed.

Through this research, the researchers provided theoretical basis and technical support for the development of more stable Pseudorabies virus vaccines, especially in terms of improving the thermal stability of vaccines and prolonging the shelf life.